Advertisement

Sean Khozin, MD, MPH, Named New Chief Executive Officer of ASCO’s CancerLinQ


Advertisement
Get Permission

Sean Khozin, MD, MPH, has been named Chief Executive Officer of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. A board-certified oncologist, physician-scientist, and data science expert, Dr. Khozin is a proven leader and visionary in deploying cutting-edge data science and technology solutions to advance biomedical research and patient care. He will begin his new role overseeing the continued expansion and implementation of CancerLinQ, ASCO's real-world oncology data platform designed to improve the quality of care for people with cancer and drive new research, on February 16.

Dr. Khozin will replace Cory Wiegert, who has served as CancerLinQ's Chief Executive Officer since 2018 and will depart February 12 to pursue another opportunity in the health-care sector.

“Dr. Khozin's extensive experience developing data science and technology initiatives for medicine makes him an ideal leader for CancerLinQ at this time as it expands and builds on the solid foundation his predecessor, Mr. Cory Wiegert, established,” said ASCO Chief Executive Officer and CancerLinQ Board of Governors Chair Clifford A. Hudis, MD, FACP, FASCO. “We greatly appreciate Cory's service to CancerLinQ during the last few critical and formative years and wish him continued success. Cory has helped set us up to deepen CancerLinQ's core quality improvement platform for oncologists and data analytics services for the broader cancer community, and Sean has the vision and experience to lead through this next exciting phase.”

As Chief Executive Officer of CancerLinQ, Dr. Khozin will be tasked with implementing the vision and priorities of CancerLinQ's independent Board of Governors, furthering ASCO's strategic goals. This includes delivering new and existing quality improvement and care delivery tools to oncology practices; ensuring that valuable insights from CancerLinQ data are obtained and published for the benefit of the entire oncology community; identifying and securing opportunities for further collaboration with government agencies, providers, academia, and others; and increasing the number of oncology practices participating in CancerLinQ to learn from ever more robust data.


“I am honored to lead CancerLinQ into its next phase of growth and help shape the future of this organization. I look forward to working with a remarkably talented team and a broad range of collaborators to advance CancerLinQ's mission to rapidly improve the quality of cancer care."
— Sean Khozin, MD, MPH

Tweet this quote

“I am honored to lead CancerLinQ into its next phase of growth and help shape the future of this organization,” said Dr. Khozin. “I look forward to working with a remarkably talented team and a broad range of collaborators to advance CancerLinQ's mission to rapidly improve the quality of cancer care."

Previous Roles

Dr. Khozin has more than a decade of leadership experience in health technology, regulation, clinical research, and data science, including the application of artificial intelligence and machine learning in biomedical research, therapeutic development, and care delivery. In his most recent position as Global Head of Data Strategy and Data Science Innovation at Janssen R&D, he led a worldwide multidisciplinary team charged with implementing pioneering data science solutions to support the development of innovative medicines.

Dr. Khozin joined Janssen R&D from the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence, where he led the center's bioinformatics, regulatory science, and clinical trial innovation efforts. He was also the founding Executive Director of Information Exchange and Data Transformation (INFORMED), FDA's first data science and technology incubator designed as an entrepreneurial sandbox for developing next-generation solutions aimed at improving biomedical research and advancing national public health priorities.

Prior to his tenure in federal government, Dr. Khozin was the cofounder of Hello Health, a technology company focused on developing integrated telemedicine, point-of-care data visualization, and advanced analytical solutions for optimizing patient care and clinical research. The company's core technology offerings were first operationalized in a multidisciplinary network of clinics called SKMD that Dr. Khozin had founded and where he served as Chief Medical Officer.

More About CancerLinQ

CancerLinQ aims to support physicians, care teams, and researchers in learning from everyone with cancer—rather than being limited to the 3% to 5% of adult patients who participate in clinical trials—by using real-world data collected through clinical care.

In 2020, CancerLinQ launched two products to improve health-care operations, enhance the quality of patient care, and facilitate new research. First was the SmartLinQ QOPI Certification Pathway, which empowers oncology practices to automate quality measure tracking and reporting for participation in ASCO's quality certification program. Second was the new CancerLinQ Discovery research platform, which offers researchers an easy way to access real-world cancer care data for analysis, a streamlined data request process, and a personalized analytics environment.

Containing 4.2 million patient records from more than 70 cancer centers and growing, the CancerLinQ database is one of the most comprehensive data sets of its kind and is used to uncover previously unseen patterns in patient characteristics and outcomes. Since its inception, CancerLinQ has established numerous collaborations with government, nonprofit, and industry partners, including the FDA, the National Cancer Institute, the American Society of Radiation Oncology, and AstraZeneca.

CancerLinQ and CancerLinQ Discovery are products of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement